Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-10
2005-05-10
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S551000
Reexamination Certificate
active
06890919
ABSTRACT:
The present invention provides novel compounds of Formula I:The invention further relates to pharmaceutical compositions comprising compounds of Formula I and to methods of using compounds of Formula I to treat neuropsychiatric disorders (e.g., psychosis, depression, schizophrenia).
REFERENCES:
patent: 3347849 (1967-10-01), Schmutz et al.
patent: 3367930 (1968-02-01), Schmutz et al.
patent: 3412193 (1968-11-01), Coppola
patent: 3444169 (1969-05-01), Howell et al.
patent: 3539573 (1970-11-01), Schmartz et al.
patent: 3546226 (1970-12-01), Schmartz et al.
patent: 3663696 (1972-05-01), Howell et al.
patent: 3681357 (1972-08-01), Howell et al.
patent: 5068437 (1991-11-01), Kazan et al.
patent: 5393752 (1995-02-01), Liegeois et al.
patent: 5538965 (1996-07-01), Tehim et al.
patent: 5576314 (1996-11-01), Power et al.
patent: 5602120 (1997-02-01), Fu et al.
patent: 5602121 (1997-02-01), Fu
patent: 5700445 (1997-12-01), Fu et al.
patent: 5703072 (1997-12-01), Power et al.
patent: 5798350 (1998-08-01), Tehim et al.
patent: 5814628 (1998-09-01), Fu et al.
patent: 5834459 (1998-11-01), Fu
patent: 5968478 (1999-10-01), Fu et al.
patent: 5976497 (1999-11-01), Pollak et al.
patent: 5998414 (1999-12-01), Wang et al.
patent: 6103715 (2000-08-01), Tehim et al.
patent: 422 793 (1967-04-01), None
patent: 436297 (1967-11-01), None
patent: 450 426 (1968-04-01), None
patent: 1164360 (1969-09-01), None
patent: WO 9517400 (1995-06-01), None
patent: WO 9618621 (1996-06-01), None
patent: WO 9618622 (1996-06-01), None
patent: WO 9618623 (1996-06-01), None
patent: WO 9618630 (1996-06-01), None
patent: WO 9801164 (1998-01-01), None
patent: WO 9807711 (1998-02-01), None
patent: WO 9837064 (1998-08-01), None
patent: WO 9900386 (1999-01-01), None
patent: WO 9931267 (1999-06-01), None
Edward J. Warawa et al., “Behavioral Approach to Nondyskinetic Dopamine Antagonists: Identification of Seroquel,” J. Med. Chem. vol. 44, Feb. 1, 2001, pp. 372-289.
Ahlenius, S., et al., Involvement of Extrapyramidal Motor Mechanisms in the Suppression of Locomotor Activity by Antipsychotic Drugs: A Comparison Between the Effects Produced by Pre- and Post-Synaptic Inhibition by Dopaminergic Neurotransmission, Pharmac., Biochem. & Behavior, vol. 24, pp. 1409-1415 (986).
Bartl, V., et al., Neurotropic and Psychotropic Agents. LXV: 8-Chloro and 8-Isopropyl-6-Piperazinobenzo(b)Pyrido[3,2-f], Thiepin, Collection Czech. Community (vol. 38), pp. 2778-2787 (1973).
Bartl, V., et al., Neurotropic and Psychotropic Agents. LXI: Derivatives of 6-Piperazinobenzo[b]Pyrido[3,2-f]Thiepin, Collection Czech. Chem. Community (vol. 38), pp. 1693-1699 (1973).
Casey, D.E., Extrapyramidal Syndromes, CMS Drugs, 5 Supp., pp. 1-12 (1996).
Farde, L., et al., Position Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine, Arch. Gen. Psychiatry, vol. 49, pp. 538-544 (1992).
Farde, L., et al., Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated with Antipsychotic Drugs, Arch. Gen. Psychiatry, vol. 45, pp. 71-76 (1988).
Jegouzo, A., et al., Comparative oxidation of toxapine and clozapine by human neutrophils, Fundam. Clin. Pharmacol. vol. 13, pp. 113-119 (1999).
Jiler, J., et al., Neurotrope Und Psychotrope Substanzen. XIX: 8-Halogenderivate von 10-(4-Methylpiperzino)-10,11-Dihydrodibenzo(b,f)Thiepin und Verwandte Substanzen, Collection Czech. Chem. Community (vol. 33), pp. 1831-1845 (1968).
Kapur, S., et al., Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis, Am. J. Psychiatry, vol. 158:3, pp. 360-369 (Mar. 2001).
Kapur, S., et al., Antipsychotic agents differ in how fast they come of the dopamine D2 receptors. Implications for atypical antipsychotic action, J. Psych. & Neuroscience, vol. 25, No. 2, pp. 161-166 (2000).
Kapur, S., et al., Are Animal Studies of Antipsychotics Appropriately Dosed?: Lessons From the Bedside to the Bench, Can. J. Psychiatry, vol. 45, pp. 241-245 (2000).
Liegeois, J.F., et al., Pyrodibenzoxazepine and Pyridobenzothiazepine Derivatives as Potential Central Nervous System Agents: Synthesis and Neurochemical Study, J. Med. Chem. vol. 37, pp. 519-525, 1994.
Moore, K., Interactions between Prolactin and Dopaminergic Neurons, Biology of Reproduction, vol. 36, pp. 47-58 (1987).
Petz, K., et al., Neurotrope and Psychotrope Substanzen. XXV: Uber dle in 8-Stellung Durch die Methyl-, Tert-Butyl-, Methoxy-, Methylthio-, und methansuffonylgruppe Substituterian 10-(4-Methylpiparazino)-10,11-Dihydrodibenzo(b,f)Thiepin-Derivate, Collection Czach. Chem. Community (vol. 33), pp. 1895-1910 (1968).
Robertson, G. et al., Induction Patterns of Fos-Like Immunoreactivity in the Forebrain as Predictors of Alypical Antipsychotic Activity, Jnl. Pharmacol. & Exper. Therap. vol. 271, No. 2, pp. 1056-1066, 1994.
Seeman, P. et al., Deriving the therapeutic concentrations for clozapine and hatoperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2receptor varies with the affinity of the competing radioligand, Eur. Jnl of Pharmac., Molecular Pharmac. Section 291, pp. 59-68, (1993).
Seeman, P. et al., Antipsychotic drugs with alicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors, Molecular Psych. vol. 3, pp. 123-134, (1998).
Seeman, P. et al., Rapid release of Antipsychotic Drugs From Dopamine D2Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawl fo Ciozapine or Quetispine. Am. J. Psychiatry.
Uetrcht, J. et al., Structural features associated with reactive metabolite formation in clozapine analogues, Chemico-Biological Interactions, vol. 104, pp. 117-129 (1997).
Uetrecht, J. et al., Reactive metabolites and agranulocytosis, Eur. Jnl Haemotology, vol. 57, pp. 83-88 (1998).
Wadenberg, M. et al., Dopamine D2receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats, Psychopharmacology, vol. 150, pp. 420-429 (2000).
Hans O. Kalkman et al., The role of D2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat, British J. of Phamacology, 124:1550-1558 (1998).
K. H. McAllister et al., “Clozapine reversal of the deficits in coordinated movement induced by D2 receptor blockade does not depend upon antagonism of α2 andrenoceptors,” Naunym-Schmiedeberg's Arch. Pharmacol. 360:603-608 (1999).
Philip Seemane et al., “Role of dopamine D2, D4 and serotonin2A receptors in antipsychotic and anticataleptic action,” J. Psychophamacology, 11(1), pp. 15-17 (1997).
Kapur Shitij
McClelland Robert
Harness & Dickey & Pierce P.L.C.
Kifle Bruck
LandOfFree
Atypical antipsychotic agents having low affinity for the D2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Atypical antipsychotic agents having low affinity for the D2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Atypical antipsychotic agents having low affinity for the D2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3429816